Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer

Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer

Show other versions (1)

Introduction: To evaluate the efficacy and safety of Carboplatin plus Paclitaxel in patients with advanced locoregional recurrence and metastatic endometrial cancer. Patient and Method: 32 eligible patients (median age 62, range 41-72) with measurable endometrial cancer were treated with Carboplatin...

Full description

Bibliographic Details
Main Authors:	Hamid Attarian, H Rezvani, M GHadyani, S Attarian, A Okhovatian, A Khosravi
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2009-09-01
Series:	International Journal of Hematology-Oncology and Stem Cell Research
Subjects:	Endometrial cancer Carboplatin Paclitaxel
Online Access:	https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/215

Similar Items

Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
by: Hamid Attarian, et al.
Published: (2009-07-01)

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
by: Maojin You, et al.
Published: (2023-09-01)

Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study
by: Naoya Ikeda, et al.
Published: (2022-05-01)

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients
by: Zhenhua Du, et al.
Published: (2015-07-01)

Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models
by: Yanxiu Guo, et al.
Published: (2018-01-01)

Long‐term survival of a patient with refractory advanced adrenocortical carcinoma after combination chemotherapy with paclitaxel and carboplatin plus mitotane
by: Yuki Kobayakawa, et al.
Published: (2022-07-01)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
by: Go Makimoto, et al.
Published: (2014-01-01)

Inflammation of Actinic Keratoses Induced by Combination of Carboplatin and Paclitaxel: Two Case Reports
by: Špela Šuler Baglama, et al.
Published: (2022-12-01)

S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
by: Anne S. Tsao, MD, MBA, et al.
Published: (2024-12-01)

Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals <i>CSF3</i> as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens
by: Pritsana Raungrut, et al.
Published: (2024-12-01)

Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis
by: Wenjian Gong, et al.
Published: (2023-07-01)

rare cause of recurrent haemolytic anaemia: carboplatin and paclitaxel-induced autoimmune haemolytic anaemia
by: Pitchaporn Yingchoncharoen, et al.
Published: (2023-02-01)

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)
by: Ticiana A. Leal, et al.
Published: (2022-11-01)

Definitive chemoradiotherapy with Carboplatin Plus Paclitaxel for Unresectable Locally Advanced Thymic Carcinoma: A case series
by: Koichiro Nozaki, et al.
Published: (2024-12-01)

Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy
by: Melek Kandemir, et al.
Published: (2015-12-01)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Bruno Chauffert, et al.
Published: (2023-01-01)

Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis
by: Yu Jin Kim, et al.
Published: (2024-08-01)

Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
by: Yingkai Chen, et al.
Published: (2022-06-01)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
by: Katsurada N, et al.
Published: (2020-02-01)

Neoadjuvant pembrolizumab-carboplatin-paclitaxel in locally advanced squamous cell carcinoma of the oral cavity: A case report and literature review
by: Abdulrahman Hesham, et al.
Published: (2024-09-01)

POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma
by: Sheela Rao, et al.
Published: (2022-08-01)

Comparison of survival and adverse effect profile in patients with esophageal cancer treated with the combination of carboplatin and paclitaxel vs. 5-flourouracil and cisplatin
by: N. Nisar, et al.
Published: (2022-09-01)

The Toxic Effect of Silibinin and Paclitaxel Combination on Endometrial Cancer Cell Line
by: Ameneh Basiri, et al.
Published: (2016-10-01)

Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study
by: Li Jiang, et al.
Published: (2022-12-01)

Design and Characterization of Carboplatin and Paclitaxel Loaded PCL Filaments for 3D Printed Controlled Release Intrauterine Implants
by: Cem Varan, et al.
Published: (2023-04-01)

The Comparison of Neutropenia and Peripheral Neuropathy Condition as an Impact of 3-hours and 24-hour Paclitaxel Infusion of Paclitaxel-Carboplatin Chemotherapy on Ovarian Cancer Patients
by: Primandono Perbowo, et al.
Published: (2019-07-01)

Durable remission in a patient with ERBB2-amplified recurrent mucinous ovarian carcinoma treated with Trastuzumab-Carboplatin-Paclitaxel
by: Alexander J. Neil, et al.
Published: (2023-08-01)

Advanced papillary serous carcinoma of the uterine cervix: a case with a remarkable response to paclitaxel and carboplatin combination chemotherapy
by: Tomoyuki Shirase, et al.
Published: (2012-01-01)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
by: Furubayashi N, et al.
Published: (2020-10-01)

Efficacy Comparison Between Weekly and Triweekly Regimens of Carboplatin-paclitaxel in Non-small Cell Lung Cancer
by: Serdar ATA, et al.
Published: (2023-09-01)

A phase II feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (YLOG0114)
by: Hiroyuki Sakashita, et al.
Published: (2022-05-01)

Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer
by: Masafumi Yasunaga, et al.
Published: (2022-09-01)

Development and Evaluation of a Quantitative Systems Pharmacology Model for Mechanism Interpretation and Efficacy Prediction of Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Patients with Non-Small-Cell Lung Cancer
by: Chen-Yu Wang, et al.
Published: (2024-02-01)

Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer
by: Jonathan W. Goldman, et al.
Published: (2019-11-01)

Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck
by: Hideki Tanaka, et al.
Published: (2023-11-01)

PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials
by: Francisco Cezar Aquino de Moraes, et al.
Published: (2023-11-01)

A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck
by: Tomohiro Enokida, et al.
Published: (2020-03-01)

A case of metastatic basal cell carcinoma treated with carboplatin and paclitaxel
by: Chryssoula Papageorgiou, et al.
Published: (2023-01-01)

A case of hyponatremia attributed to carboplatin-induced syndrome of inappropriate anti-diuretic hormone
by: Shohei Tanabe, et al.
Published: (2023-08-01)

Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
by: Minami Seigo, et al.
Published: (2013-01-01)